about
MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stressPharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.Nuclear receptors and drug metabolism for the personalization of cancer therapy.HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.Genetic biomarkers for hepatocellular cancer risk in a caucasian population.Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.Pharmacology of epidermal growth factor inhibitors.Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.A Pharmacogenetic Survey of Androgen Receptor (CAG)N and (GGN)N Polymorphisms in Patients Experiencing Long Term Side Effects after Finasteride DiscontinuationA Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based TherapyThe genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practiceTumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapyrs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy.MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatinGermline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patientsClonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC)Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementationCirculating-Free DNA Analysis in Hepatocellular Carcinoma: A Promising Strategy to Improve Patients' Management and Therapy OutcomesA TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancerGenetic markers of the host to predict the efficacy of colorectal cancer targeted therapyGermline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRIPharmacogenetics of the systemic treatment in advanced hepatocellular carcinomaNew Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach
P50
Q33579778-370D8CAF-854F-41CB-A245-CDC30A7A9B75Q34975510-F1745B88-18D6-4451-AFA6-69B7B15DCE23Q35860201-3B744F84-87EA-4B36-A897-E6CF3748548CQ36915163-93868FFD-C154-4CB7-878B-DC5F8DE990E5Q37190172-D5A01D0D-A9BA-445F-A38D-A4E1780ED692Q37286470-E2BF079D-C94B-4075-9BAC-0B61CA0418E2Q37330894-E9F3921D-1967-470A-B67B-861E2BFF077DQ38166454-4CFCCD96-A530-42DE-ADA1-C5D3C9C0ECE4Q38509294-82CF52D2-BE51-4E87-91F7-9339E1909FECQ38679229-53FB9BEC-103F-4E6A-B60E-00042438DE04Q38704025-0A97631C-D330-4562-938C-D60F81D7F03AQ38707311-74129B2E-2BB7-46C7-B8CF-0FD7ABC47D3CQ38937177-B195355B-095B-492E-86C7-B280D64AA08CQ40291987-C4BC8FDB-BACD-4343-A20E-811FF17DD6A9Q42328270-F9A047F2-52C4-4D73-8DDA-CB3801929377Q42695128-D05DE2A4-00EE-4910-9F46-2F15A4D073A9Q42700517-33C1C1C6-887A-4B5B-BBAD-02F02BA68FBAQ43358640-62036141-0539-49EB-812A-4BEF5BE5E058Q45563347-D3604EE7-096F-471E-AE79-DB891F9B5FEAQ53580315-55842953-0B5E-46A3-8CAC-DA407EC9FD18Q55259197-A659BCA2-2435-4887-BA86-B9ACF5B9825FQ55280979-ACC0000D-88D8-4730-9E68-B7BADB46FDB6Q56100649-E66B7912-4C69-4736-ACE8-D63067917E71Q58584090-A191F883-35BE-4A77-BC61-C5F243886113Q58587038-A5BA248A-2F55-49F4-82C5-8DD2150CE171Q63884146-9287498C-6F78-43DF-9E34-0C18A9F27FCDQ64929607-1C08CA8C-9204-4F96-A63C-1CE614BBB7C2Q64980874-6A683D88-0C90-4698-9978-A8A072405099Q85831913-12868A19-1631-4773-B04D-D37B0317C994Q90045223-B53EFFC6-D7E8-4DA2-B9FC-254E47785151Q90460653-A42421CC-D2A4-4367-A831-03CB45B00DF9Q90744514-BDED7AE6-41A2-49D3-AABA-79404CBD350EQ91146934-DB396CE5-4D92-490F-A8B2-34755BEC819BQ91230219-045FB9F3-04FB-4102-81F5-9289DD00F31CQ91819560-74A1A224-2FEE-43E8-8D24-8E1C6187193CQ92073896-72488B46-036F-4620-BB27-CA73D0BDDF5DQ92625988-0284210E-7C55-4C8F-8CA3-5A3B5B8A79DCQ92733309-478867E0-6FCB-46B2-A55A-599AE5345D34
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elena De Mattia
@ast
Elena De Mattia
@en
Elena De Mattia
@es
Elena De Mattia
@nl
type
label
Elena De Mattia
@ast
Elena De Mattia
@en
Elena De Mattia
@es
Elena De Mattia
@nl
prefLabel
Elena De Mattia
@ast
Elena De Mattia
@en
Elena De Mattia
@es
Elena De Mattia
@nl
P108
P106
P1153
25635377900
P21
P31
P496
0000-0003-4948-8767